

Supplementary Table 1. Patient baseline characteristics of the Child-Pugh class B subgroup

	MET (n=29)	Sorafenib (n=19)	P-value
Mean age±SD (yrs)	56.2±11.5	55.7±4.5	0.832
Gender			0.151
Male	27 (93.1)	15 (78.9)	
Female	2 (6.9)	4 (21.1)	
Etiology			0.130
HBV	23 (79.3)	18 (94.7)	
HCV	3 (10.3)	1 (5.3)	
Alcohol	2 (6.9)	0 (0.0)	
Others	1 (3.4)	0 (0.0)	
Child-Pugh score			0.520
7	16 (55.2)	12 (63.2)	
8	6 (20.7)	4 (21.1)	
9	7 (24.1)	3 (15.8)	
Tumor maximal diameter	12.9±5.0	10.1±5.0	0.069
Tumor number			0.223
Solitary	6 (20.7)	7 (36.8)	
Multiple	23 (79.3)	12 (63.2)	
PVTT			0.972
Vp2	3 (10.3)	2 (10.5)	
Vp3	14 (48.3)	9 (47.4)	
Vp4	12 (41.4)	8 (42.1)	
Extrahepatic metastasis	16 (55.2)	10 (52.6)	0.864
mUICC			0.842
III	4 (13.8)	3 (15.8)	
IVA	9 (31.0)	6 (31.6)	
IVB	16 (55.2)	10 (52.6)	
Serum AFP level (ng/dL)			0.521
<400	11 (37.9)	9 (47.4)	
≥400	18 (62.1)	10 (52.6)	
Previous treatment	12 (41.4)	11 (57.9)	0.268

Values are presented as mean±SD or n (%).

MET, metronomic chemotherapy; HBV, hepatitis B virus; HCV, hepatitis C virus; PVTT, portal vein tumor thrombosis; mUICC, modified UICC staging; AFP, alpha-fetoprotein.